Antagonists of Il-6 to Prevent Or Treat
Total Page:16
File Type:pdf, Size:1020Kb
(19) TZZ ¥_ _T (11) EP 2 376 126 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 16/24 (2006.01) 20.12.2017 Bulletin 2017/51 (86) International application number: (21) Application number: 09830695.4 PCT/US2009/006266 (22) Date of filing: 24.11.2009 (87) International publication number: WO 2010/065077 (10.06.2010 Gazette 2010/23) (54) ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS ANTAGONISTEN VON IL-6 ZUR PRÄVENTION ODER BEHANDLUNG VON THROMBOSE ANTAGONISTES D IL-6 POUR PRÉVENIR OU TRAITER LA THROMBOSE (84) Designated Contracting States: • MATSUYAMA MASASHI ET AL: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR "Anti-interleukin-6 receptor antibody HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL (tocilizumab) treatment of multicentric PT RO SE SI SK SM TR Castleman’s disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, (30) Priority: 05.02.2009 US 366567 TOKYO, JP; BIOSCIENCES INFORMATION 14.07.2009 US 502581 SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 25.11.2008 US 117811 P January 2007 (2007-01-01), pages 771-774, 25.11.2008 US 117861 P XP002696891, ISSN: 0918-2918, DOI: 24.02.2009 US 391717 10.2169/INTERNALMEDICINE.46.6262 06.03.2009 US 399156 • EMILLE D ET AL: "ADMINISTRATION OF AN 25.11.2008 US 117839 P ANTI-INTERLEUKIN-6 MONOCLONAL 24.02.2009 US 391615 ANTIBODY TO PATIENTS WITH ACQUIRED IMUNODEFICIENCY SYNDROME AND (43) Date of publication of application: LYMPHOMA: EFFECT ON LYMPHOMA GROWTH 19.10.2011 Bulletin 2011/42 AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OFHEMATOLOGY, US, vol. (73) Proprietor: AlderBio Holdings LLC 84, no. 8, 15 October 1994 (1994-10-15), pages Las Vegas, NV 89109 (US) 2472-2479, XP001088120, ISSN: 0006-4971 • M. H. ZAKI ET AL: "Proc Am Soc Clin Oncol", 2003 (72) Inventor: SMITH, Jeffrey, T.L. ASCO ANNUAL MEETING - DEVELOPMENTAL Bellevue THERAPEUTICS - CLINICAL PHARMACOLOGY WA 98004 (US) AND IMMUNOTHERAPY , vol. 22, 697, 2003, XP055045899, Retrieved from the Internet: (74) Representative: Boult Wade Tennant URL:http://www.asco.org/ASCOv2/Meetings/Ab Verulam Gardens stracts?&vmview=abst_detail_view&confID=23 70 Gray’s Inn Road &abstractID=100701 [retrieved on 2012-11-27] London WC1X 8BT (GB) • BATAILLE R ET AL: "Biologic effects of anti-interleukin-6 murine monoclonal antibody in (56) References cited: advanced multiple myeloma", BLOOD, WO-A1-2004/039826 WO-A2-2008/065378 AMERICAN SOCIETY OFHEMATOLOGY, US, vol. WO-A2-2008/144763 US-A1- 2007 292 420 86, no. 2, 15 July 1995 (1995-07-15), pages US-B2- 7 169 573 685-691, XP002448659, ISSN: 0006-4971 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 376 126 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 376 126 B1 • G STRASSMANN ET AL: "Evidence for the • NISHIMOTOET AL.: ’Mechanismsand pathologic involvement of interleukin 6 in experimental significances in increase in serum interleukin-6 cancer cachexia.", JOURNAL OF CLINICAL (IL-6) and soluble IL-6 receptor after INVESTIGATION, vol. 89, no. 5, 1 May 1992 administration of an anti-IL-6 receptor antibody, (1992-05-01), pages 1681-1684, XP055045903, tocilizumab, in patients with rheumatoid arthritis ISSN: 0021-9738, DOI: 10.1172/JCI115767 and Castleman disease.’ BLOOD vol. 112, no. 10, • STRASSMANN G ET AL: "INHIBITION OF 15 November 2008, pages 3959 - 3964 EXPERIMENTAL CANCER CACHEXIA BY • ’LAB TESTS ONLINE. Hypercoagulable ANTI-CYTOKINE AND Disorders.’, [Online] 01 March 2008, Retrieved ANTI-CYTOKINE-RECEPTOR THERAPY", from the Internet: CYTOKINES AND MOLECULAR THERAPY, <URL:http://web.archive.org/web/20080301224 DUNITZ, LONDON, GB, vol. 1, no. 2, 1 January 129/http://www.labtestsonline.org/understan 1995 (1995-01-01) , pages 107-113, XP008043222, ding/conditions/hypercoagulable_disorders-6 .h ISSN: 1355-6568 tml> [retrieved on 2010-06-17] • KLEIN ET AL: "Murine anti-interleukin-6 • Thomson Reuters - Integrity: "Huamnized monoclonal antibody therapy for a patient with Anti-IL-6 monoclonal antibody - Heavy and light plasma cell leukemia.", BLOOD, vol. 78, no. 5, 1 chains", , 16 January 2008 (2008-01-16), September 1991 (1991-09-01), pages 1198-1204, XP055292638, Retrieved from the Internet: XP055045905, ISSN: 0006-4971 URL:https://integrity.thomson-pharma.com/i • KAORI FUJIMOTO-OUCHI ET AL: "Capecitabine ntegrity/xmlxsl/pk_prod_list.xml_prod_list improves cancer cachexia and normalizes IL-6 _card_pr?p_id=468410 [retrieved on 2016-08-01] and PTHrP levels in mouse cancer cachexia • Gerhard A Kalweit ET AL: "Markers of Activated models", CANCER CHEMOTHERAPY AND Hemostasis and Fibrinolysis in Patients with PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. Pulmonary Malignancies", Thrombosis 59, no. 6, 29 September 2006 (2006-09-29), pages Research, vol. 97, no. 3, 1 February 2000 807-815, XP019490080, ISSN: 1432-0843 (2000-02-01), pages105-111, XP055199314, ISSN: • SUMIE TAMURA ET AL: "Involvement of human 0049-3848, DOI: 10.1016/S0049-3848(99)00161-9 interleukin6 in experimentalcachexia induced by • ZAKI M H ET AL: "CNTO 328, A monoclonal a human uterine cervical carcinoma xenograft.", antibody to IL-6, inhibits human tumor-induced CLINICAL CANCER RESEARCH, vol. 1, 1 January cachexia in nude mice", INTERNATIONAL 1995 (1995-01-01), pages 1353-1358, JOURNAL OF CANCER, JOHN WILEY & SONS, XP055045909, INC, US, vol. 111, 1 January 2004 (2004-01-01), • NISHIMOTO ET AL.: ’Improvement in pages 592-595, XP003012697, ISSN: 0020-7136, Castleman’s disease by humanized DOI: 10.1002/IJC.20270 anti-interleukin-6 receptor antibody therapy.’ • TRIKHA MOHIT ET AL: "Targeted BLOOD vol. 95, no. 1, 2000, pages 56 - 61 anti-interleukin-6 monoclonal antibody therapy • ’LAB TESTS ONLINE. D-Dimer: The Test.’, for cancer: a review of the rationale and clinical [Online] 20 October 2008, Retrieved from the evidence", CLINICAL CANCER RESEARCH, THE Internet: AMERICAN ASSOCIATION FOR CANCER <URL:http://web.archive.org/web/20071020065 RESEARCH, US, vol. 9, no. 13, 1 January 2003 024/http://www.labtestsonline.org/understan (2003-01-01), pages 4653-4665, XP002543280, ding/analytes/d_dimer/test.html> [retrieved on ISSN: 1078-0432 2010-06-17] • M.Oya: "High PreoperativePlasma D-dimer Level • BLAY ET AL.: ’Role of Interleukin-6 in the is Associated with Advanced Tumor Stage and Paraneoplastic inflammatory syndrome Short Survival After Curative Resection in associated with renal cell carcinoma.’ INT J Patients with Colorectal Cancer", JAPANESE CANCER vol. 72, no. 3, 1997, pages 424 - 430 JOURNALOF CLINICAL ONCOLOGY., vol.31, no. • CATA ET AL.: ’The effects of thalidomide and 8, 1 August 2001 (2001-08-01) , pages 388-394, minocycline on taxol-induced hyperalgesia in XP55293677, JP ISSN: 0368-2811, DOI: rats.’ BRAIN RES vol. 1229, 10 September 2008, 10.1093/jjco/hye075 pages 100 - 110 • RIDKER ET AL.: ’Rosuvastatin to prevent vascular events in men and women with elevated C- reactive protein.’ NEW ENG J MED vol. 359, no. 21, 20 November 2008, pages 2195 - 2207 2 EP 2 376 126 B1 Description BACKGROUND OF THE INVENTION 5 Field of the Invention [0001] This invention is an extension of Applicants’ prior invention relating to novel anti-IL-6 antibodies and novel therapies and therapeutic protocols using anti-IL-6 antibodies, preferably those described herein. In particular, this invention pertains to an anti-IL-6 antibody comprising a VL polypeptide of SEQ ID NO:709 and a light chain constant 10 region of SEQ ID NO: 586; and a VH polypeptide of SEQ ID NO:657 and a heavy chain constant region of SEQ ID NO: 588 for use in a method of treating a patient having an advanced cancer associated with hypercoagulation, wherein the anti-IL-6 antibody is aglycosylated. [0002] In another embodiment the invention provides novel combination therapies wherein the anti-IL-6 antibody of the invention is administered in combination with at least one other therapeutic compound e.g., a statin,including but 15 not limited to atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simv- astatin, or any combination thereof; a chemotherapeutic agent such as VEGF antagonists, EGFR antagonists, platins, taxols, irinotecan, 5-fluorouracil, gemcitabine, leucovorin, steroids, cyclophosphamide, melphalan, vinca alkaloids (e.g., vinblastine, vincristine, vindesine and vinorelbine), mustines, tyrosine kinase inhibitors, radiotherapy, sex hormone an- tagonists, selective androgen receptor modulators, selective estrogen receptor modulators, PDGF antagonists, TNF 20 antagonists, IL-1 antagonists, interleukins (e.g. IL-12 or IL-2), IL-12R antagonists, toxin conjugated monoclonal antibod- ies, tumor antigen specific monoclonal antibodies, Erbitux™ , Avastin™, Pertuzumab, anti-CD20 antibodies, RituxanTM, ocrelizumab, ofatumumab, DXL625, Herceptin.™, or any combination thereof; or an an anti-coagulant such as abciximab (ReoPro™), acenocoumarol, antithrombin, argatroban, aspirin, bivalirudin (Angiomax™), clopidogrel, dabigatran, da- bigatran, etexilate, (Pradaxa™/Pradax™), desirudin (Revasc™/Iprivask™), dipyridamole, eptifibatide (Integrilin™), fon- 25 daparinux, heparin, hirudin, idraparinux, lepirudin (Refludan™), low molecular weight heparin, Melagatran, phenindione, phenprocoumon, ticlopidine, tirofiban (Aggrastat™), warfarin, ximelagatran, ximelagatran (Exanta™/ Exarta™), or any combination thereof. Description of Related Art 30 [0003] Thrombosis is a significant cause of mortality in cancer patients. Bick, N Engl J Med 349:109-111 (2003). For example, serious, life-threatening thrombotic events occur in approximately 6% of lung cancer patients. Alguire et al., J Clin Oncol 2004 Vol 22 (July 15th Supplement) No. 14S: 8082. Cancer patients often exhibit hypercoagulation, in which the coagulation system has an increased clotting tendency. Rickles and Edwards, Blood 62:14-31 (1983).